Baidu
map

Neuropsychopharmacol:研究发现吸烟越早大脑越薄

2014-03-18 陈雪莹 生命时报

抽烟有害健康,抽烟越早,危害就越大。据英国《每日邮报》3月3日报道,美国加州大学洛杉矶分校的研究者发现,从青少年时期就开始抽烟,会让大脑变薄;年轻男女抽烟的时间越长,他们大脑区域中负责决策制定的灰质数量就会越少,对香烟的渴望也就越为强烈。研究人员对年轻吸烟者的大脑发生如此明显的变化而感到吃惊。这一发现也有助于解释为什么从青少年起就开始吸烟的人难以戒断烟瘾的原因。 研究人员对42名年龄在16~21

抽烟有害健康,抽烟越早,危害就越大。据英国《每日邮报》3月3日报道,美国加州大学洛杉矶分校的研究者发现,从青少年时期就开始抽烟,会让大脑变薄;年轻男女抽烟的时间越长,他们大脑区域中负责决策制定的灰质数量就会越少,对香烟的渴望也就越为强烈。研究人员对年轻吸烟者的大脑发生如此明显的变化而感到吃惊。这一发现也有助于解释为什么从青少年起就开始吸烟的人难以戒断烟瘾的原因。

研究人员对42名年龄在16~21岁之间的男女志愿者的大脑进行了细致扫描,这些志愿者中有一部分人从未抽过烟,其余的人平均每天抽烟6~7支。扫描结果显示,年轻人的吸烟量越多,他们的右侧脑岛就越为稀薄。这个大脑区域参与决策制定过程和信任感的建立,主要负责人们直觉的形成。它对尼古丁高度敏感,而且也与大脑中控制渴望感和欲望的能力相连接。

研究者认为,脑岛较为稀薄会让人更难戒除烟瘾。发表在《神经心理药物学期刊》上的这一研究结果表明,从青少年时期(大脑发育的一个关键时期)就抽烟所造成的大脑变化,会让人在成年时更难以戒掉烟瘾。

原始出处:

Angelica M Morales, Dara Ghahremani, Milky Kohno, Gerhard S Hellemann and Edythe D London.Cigarette Exposure, Dependence and Craving are Related to Insula Thickness in Young Adult Smokers.Neuropsychopharmacology (3 March 2014) | doi:10.1038/npp.2014.48

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753060, encodeId=b9fa1e53060c3, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue May 20 13:13:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787139, encodeId=b1041e8713973, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jun 11 17:13:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995891, encodeId=746919958914b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 20 04:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788150, encodeId=6f541e88150af, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Nov 17 07:13:00 CST 2014, time=2014-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908161, encodeId=f3e7190816158, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Jul 06 08:13:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753060, encodeId=b9fa1e53060c3, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue May 20 13:13:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787139, encodeId=b1041e8713973, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jun 11 17:13:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995891, encodeId=746919958914b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 20 04:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788150, encodeId=6f541e88150af, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Nov 17 07:13:00 CST 2014, time=2014-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908161, encodeId=f3e7190816158, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Jul 06 08:13:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2014-06-11 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753060, encodeId=b9fa1e53060c3, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue May 20 13:13:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787139, encodeId=b1041e8713973, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jun 11 17:13:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995891, encodeId=746919958914b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 20 04:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788150, encodeId=6f541e88150af, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Nov 17 07:13:00 CST 2014, time=2014-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908161, encodeId=f3e7190816158, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Jul 06 08:13:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2015-01-20 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1753060, encodeId=b9fa1e53060c3, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue May 20 13:13:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787139, encodeId=b1041e8713973, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jun 11 17:13:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995891, encodeId=746919958914b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 20 04:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788150, encodeId=6f541e88150af, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Nov 17 07:13:00 CST 2014, time=2014-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908161, encodeId=f3e7190816158, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Jul 06 08:13:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1753060, encodeId=b9fa1e53060c3, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue May 20 13:13:00 CST 2014, time=2014-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787139, encodeId=b1041e8713973, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jun 11 17:13:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995891, encodeId=746919958914b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 20 04:13:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788150, encodeId=6f541e88150af, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Nov 17 07:13:00 CST 2014, time=2014-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908161, encodeId=f3e7190816158, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Jul 06 08:13:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]

相关资讯

PNAS:科学家解决伽利略遗留的难题——为什么白点看起来比相同体积的黑点大

科学家近日揭示了由伽利略发现的视觉错觉的神经机制。该发现提高了我们对大脑识别物体工作机制的认识。该研究由纽约大学Jens Kremkow博士领导的研究团队完成,相关报道发表在近期的PNAS杂志上。 伽利略在观测行星的时候发现了一个奇怪的现象,他发现裸眼和望远镜观察行星的形态是不一样的。直接观察行星,行星看起来会变大,并具有发光光环。这就使得金星看起来比木星大八至十倍,而事实上木星比金星大四倍。伽

J Neurosci:智力低下的神经发育分子调控机制

人类的大脑由1000亿个神经元组成,神经元与神经元之间通过多达10000个神经突触相互连接形成一个庞大而复杂的神经网络,从而行使大脑的功能。因此,神经突触的发育和功能是神经生物学研究的核心内容。脂质的主要生理功能是储存能量、构成细胞膜组份以及调控膜信号转导。脂质在神经系统中富集,且对神经系统的发育和功能起着极其重要的作用。脂代谢异常导致多种神经精神疾病。例如参与脂肪酸在体内活化利用的第一步关键酶脂

Nat Neurosci:催产素或可提升新生小鼠大脑感官

在感官丧失后,新生小鼠大脑在感官反应方面所产生的变化可通过调控催产素得到克服。《自然—神经科学》发表的这项研究结论或能够为特定神经发育障碍比如自闭症谱系障碍(ASD)等提供治疗方法。催产素是荷尔蒙的一种,由大脑释放,能够促进性兴奋、社交和情感行为。 Xiang Yu等人发现当新生小鼠在刚出生就被剥夺视觉和触觉感官时,其大脑下丘脑所产生的催产素的释放量会有所减少。剥夺幼鼠的一种感官信息也会影响其大

Memory:25岁是人生的黄金期

如果有人问人一生中什么时间是黄金记忆时间?一天中什么时间是黄金记忆时间?一年中什么时间是黄金记忆时间?可能有人会回答:一年之计在于春,一日之计在于晨,年少不努力,老大徒伤悲。对此回答你不可能人为有错,但是也未必确切,因为教育学研究成果表明,0-12岁是人一生发展最重要的阶段,是人类记忆力发展的黄金时期。在此期间,90%的记忆力已经形成。在这一时期加强对儿童的教育,将会收到事半功倍的成效。一旦错过这

Nat Neurosci.:为啥不可“一心二用”

俗话说,“一心不可二用”。日本京都大学研究人员利用日本猕猴进行实验时,从科学角度证实了这一点。 京都大学教授船桥新太郎率领的研究小组在新一期英国《自然·神经科学》杂志上报告说,同时干两件事情,不是出错,就是多花时间。这种现象被称为“双任务干扰”。但是在“双任务干扰”下,脑内到底是什么样的情形一直没有弄清。 研究小组利用日本猕猴进行了实验,让猕猴同时完成需要记忆和需要集中注意力的两项任务,结果发

PLoS One:科学家解释给人留下好印象的秘诀

想象一下你打电话给一位陌生人——潜在雇主或其他你尚未谋面但欣赏的人,你想给对方留下一个好印象,为此已提前排练了开场白。然而,你可能没有意识到的是,对方产生第一印象的时候是在你说出“你好(Hello)”的那一刻。 心理学家发现,简单的一句“你好”就已经携带了足够的信息,能让对方得出有关你的个性或是否可靠等结论。 加拿大 Lethbridge 大学心理学家 Drew Rendall 表示,人们是在

Baidu
map
Baidu
map
Baidu
map